Скачать или смотреть Monoclonal antibodies for myeloma relapsed after ASCT

Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, outlines the use of monoclonal antibody therapies for patients with multiple myeloma who relapse after autologous stem cell transplantation (ASCT). Prof. Mohty compares treatment options for patients who are lenalidomide-refractory and patients who are lenalidomide-sensitive. For lenalidomide-sensitive patients, Prof. Mohty highlights data from the Phase III POLLUX trial (NCT02076009) investigating daratumumab-lenalidomide-dexamethasone in patients with R/R multiple myeloma. For patients who are lenalidomide-refractory, Prof. Mohty discusses results from the CANDOR trial (NCT03158688), testing daratumumab-carfilzomib-dexamethasone, and the IKEMA trial (NCT03275285), investigating isatuximab-carfilzomib-dexamethasone, both in patients with R/R multiple myeloma. Finally, Prof. Mohty discusses the use of IMiDs, with reference to the APOLLO trial (NCT03180736) investigating daratumumab-pomalidomide-dexamethasone, and the ICARIA-MM trial (NCT02990338), investigating isatuximab-pomalidomide-dexamethasone. This interview took place during the 47th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2021.